Skip to main content

Advertisement

Log in

Diagnosis of Cystic Fibrosis

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that results in abnormal viscous mucoid secretions in multiple organs and whose main clinical features are pancreatic insufficiency and chronic endobronchial infection. Although it was initially defined and diagnosed based on clinical features and sweat chloride measurement, an in vivo method of assessing CFTR function, the discovery of the CFTR gene in 1989 revealed a broad spectrum of CF phenotypes associated with specific CFTR gene mutations. In this article, we will review the indications for sweat testing, alternative techniques to diagnose CF, and the approach to patients with an ambiguous or indeterminate diagnosis of CF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Davis PB, Drumm M, Konstan MW (1996) Cystic fibrosis. Am J Respir Crit Care Med 154:1229–1256

    PubMed  CAS  Google Scholar 

  2. National Newborn Screening and Genetics Resource Center (2003) National newborn screening report 2000. National Newborn Screening and Genetics Resource Center, San Antonio, TX

    Google Scholar 

  3. Andersen D (1938) Cystic fibrosis of the pandrease and its relation to celiac disease: a clinical and pathological study. Am J Dis Child 56:344–399

    Google Scholar 

  4. Di Sant'Agnese P (2001) Experiences of a pioneer researcher: discovery of the sweat electrolyte defect and the early medical history of cystic fibrosis. In: Doershuk C (ed) Cystic fibrosis in the 20th century. People, events, and progress. AM, Cleveland, OH

    Google Scholar 

  5. Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23:545–549

    PubMed  CAS  Google Scholar 

  6. Rosenstein BJ, Cutting GR (1998) The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 132:589–595

    Article  PubMed  CAS  Google Scholar 

  7. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245:1066–1073

    Article  PubMed  CAS  Google Scholar 

  8. Rowntree RK, Harris A (2003) The phenotypic consequences of CFTR mutations. Ann Hum Genet 67:471–485

    Article  PubMed  CAS  Google Scholar 

  9. Davis PB (2001) Cystic fibrosis. Pediatr Rev 22:257–264

    Article  PubMed  CAS  Google Scholar 

  10. Cystic Fibrosis Foundation (2006) Cystic fibrosis foundation patient registry. Cystic Fibrosis Foundation, Bethesda, MD

    Google Scholar 

  11. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW et al (1998) Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95:1005–1015

    Article  PubMed  CAS  Google Scholar 

  12. Wine JJ (1999) The genesis of cystic fibrosis lung disease. J Clin Invest 103:309–312

    Article  PubMed  CAS  Google Scholar 

  13. Ratjen F (2006) Restoring airway surface liquid in cystic fibrosis. N Engl J Med 354:291–293

    Article  PubMed  CAS  Google Scholar 

  14. LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr (2007) Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151:85–89

    Article  PubMed  Google Scholar 

  15. NCCLS (2000) Sweat testing: sample collection and quantitative analysis: approved guideline. National Committee for Clinical Laboratory Standards, Wayne, PA Document C34-A2. Clinical Laboratory Standards Institute formerly National Committee for Clinical Laboratory Standards

    Google Scholar 

  16. Grosse SD, Boyle CA, Botkin JR, Comeau AM, Kharrazi M, Rosenfeld M et al (2004) Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 53:1–36

    Google Scholar 

  17. Knowles MR, Durie PR (2002) What is cystic fibrosis? N Engl J Med 347:439–442

    Article  PubMed  Google Scholar 

  18. De Boeck K, Wilschanski M, Castellani C, Taylor C, Cuppens H, Dodge J et al (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627–635

    Article  PubMed  Google Scholar 

  19. Zeitlin PL (1999) Novel pharmacologic therapies for cystic fibrosis. J Clin Invest 103:447–452

    Article  PubMed  CAS  Google Scholar 

  20. Donaldson SH, Boucher RC (2007) Sodium channels and cystic fibrosis. Chest 132:1631–1636

    Article  PubMed  CAS  Google Scholar 

  21. Hamosh A, FitzSimmons SC, Macek M Jr., Knowles MR, Rosenstein BJ, Cutting GR (1998) Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 132:255–259

    Article  PubMed  CAS  Google Scholar 

  22. Wine JJ, Kuo E, Hurlock G, Moss RB (2001) Comprehensive mutation screening in a cystic fibrosis center. Pediatrics 107:280–286

    Article  PubMed  CAS  Google Scholar 

  23. Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A et al (1998) Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest 101:487–496

    Article  PubMed  CAS  Google Scholar 

  24. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ (1993) Mutations in CFTR associated with mild-disease-form Cl− channels with altered pore properties. Nature 362:160–164

    Article  PubMed  CAS  Google Scholar 

  25. O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R (2006) Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype. Pediatrics 118:1260–1265

    Article  PubMed  Google Scholar 

  26. Ren CL (2007) Pulmonary manifestations in deltaF508/R117H. Pediatrics 119:647–648

    Article  PubMed  Google Scholar 

  27. Highsmith WE, Burch LH, Zhou Z, Olsen JC, Boat TE, Spock A et al (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331:974–980

    Article  PubMed  CAS  Google Scholar 

  28. Alton EW, Currie D, Logan-Sinclair R, Warner JO, Hodson ME, Geddes DM (1990) Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 3:922–926

    PubMed  CAS  Google Scholar 

  29. Knowles MR, Paradiso AM, Boucher RC (1995) In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 6:445–455

    Article  PubMed  CAS  Google Scholar 

  30. Sauder RA, Chesrown SE, Loughlin GM (1987) Clinical application of transepithelial potential difference measurements in cystic fibrosis. J Pediatr 111:353–358

    Article  PubMed  CAS  Google Scholar 

  31. Wagener JS, Sontag MK, Accurso FJ (2003) Newborn screening for cystic fibrosis. Curr Opin Pediatr 15:309–315

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karen Z. Voter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voter, K.Z., Ren, C.L. Diagnosis of Cystic Fibrosis. Clinic Rev Allerg Immunol 35, 100–106 (2008). https://doi.org/10.1007/s12016-008-8078-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-008-8078-x

Keywords

Navigation